A phase I, randomized, double-blind, parallel, single-dose pharmacokinetic study to evaluate the biosimilarity of KM118 (proposed pertuzumab biosimilar) with reference pertuzumab (Perjeta <sup>®</sup> ) in healthy male subjects
Authors
Cai‐Xia Yang (ORCID: https://orcid.org/0000-0002-6472-1929)
Xinghe Wang (ORCID: https://orcid.org/0000-0002-4197-8545)
Yan Li (ORCID: https://orcid.org/0000-0002-7465-7705)
Yu Wang (ORCID: https://orcid.org/0000-0001-9897-6412)
Na Zhao (ORCID: https://orcid.org/0000-0002-3086-2993)
Institutions
Capital Medical University (CN)
National Institutes of Pharmaceutical Research and Development (China) (CN)
A phase I, randomized, double-blind, parallel, single-dose pharmacokinetic study to evaluate the biosimilarity of KM118 (proposed pertuzumab biosimilar) with reference pertuzumab (Perjeta ® ) in healthy male subjects
Cai‐Xia Yang, Xinghe Wang, Yan Li, Yu Wang et al.
Citations
1 citations
Journal
Annals of Medicine
Topics
HER2/EGFR in Cancer Research
Field-Weighted Citation Impact (FWCI)
1.05
article
A phase I, randomized, double-blind, parallel, single-dose pharmacokinetic study to evaluate the biosimilarity of KM118 (proposed pertuzumab biosimilar) with reference pertuzumab (Perjeta ® ) in healthy male subjects
Cai‐Xia Yang, Xinghe Wang, Yan Li, Yu Wang, Na Zhao
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
Annals of MedicineVol. 57(1)
Institutions
Capital Medical University (CN), National Institutes of Pharmaceutical Research and Development (China) (CN), Beijing Shijitan Hospital (CN)